Get the Stockscreener App
9.39
2.29%
0.21
After Hours:
9.77
0.38
+4.05%
Bridgebio Oncology Therapeutics Inc stock is traded at $9.39, with a volume of 535.60K.
It is up +2.29% in the last 24 hours and up +3.30% over the past month.
BridgeBio Oncology Therapeutics Inc, is a clinical-stage biotechnology company that aims to transform the lives of patients with cancers driven by RAS and PI3Ka, the two frequently mutated oncogenes. The Company operates in one operating and reportable segment within the United States, developing oncology therapies through various related development projects.
See More
Previous Close:
$9.18
Open:
$9.2
24h Volume:
535.60K
Relative Volume:
1.92
Market Cap:
$751.51M
Revenue:
-
Net Income/Loss:
$-83.12M
P/E Ratio:
-6.278
EPS:
-1.4957
Net Cash Flow:
$-114.50M
1W Performance:
+8.68%
1M Performance:
+3.30%
6M Performance:
-21.42%
1Y Performance:
+0.00%
1-Day Range:
$9.05
$9.515
1-Week Range:
$8.11
$9.515
52-Week Range:
$8.08
$14.87
Bridgebio Oncology Therapeutics Inc Stock (BBOT) Company Profile
Name
Bridgebio Oncology Therapeutics Inc
Sector
Industry
Phone
857 702 0377
Address
256 E. GRAND AVENUE, SUITE 104, SOUTH SAN FRANCISCO
Compare BBOT vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BBOT
Bridgebio Oncology Therapeutics Inc
|
9.39 | 734.70M | 0 | -83.12M | -114.50M | -1.4957 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Bridgebio Oncology Therapeutics Inc Stock (BBOT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-11-26 | Initiated | Stifel | Buy |
| Jan-09-26 | Initiated | Raymond James | Outperform |
| Dec-05-25 | Initiated | Morgan Stanley | Overweight |
| Sep-17-25 | Initiated | Leerink Partners | Outperform |
| Sep-15-25 | Initiated | H.C. Wainwright | Buy |
| Aug-15-25 | Initiated | Piper Sandler | Overweight |
View All
Bridgebio Oncology Therapeutics Inc Stock (BBOT) Latest News
BridgeBio Oncology Therapeutics reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Bridgebio Oncology Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView — Track All Markets
BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - ChartMill
What date does BridgeBio Oncology Therapeutics, Inc's (BBOT) report EarningsEarnings Calendar & Announcement - Zacks Investment Research
BBOT SEC FilingsBridgeBio Oncology Therapeutics, Inc 10-K, 10-Q, 8-K Forms - Stock Titan
BridgeBio Oncology Therapeutics appoints Peter Lebowitz to board of directors - Investing.com Australia
BridgeBio Oncology Therapeutics appoints Peter Lebowitz to board of directors By Investing.com - Investing.com South Africa
BridgeBio Oncology (BBOT) director receives 63,350 stock options award - Stock Titan
BridgeBio Oncology (NASDAQ: BBOT) director Peter Lebowitz files initial Form 3 - Stock Titan
63M shares registered for resale by BridgeBio Oncology (NASDAQ: BBOT) - Stock Titan
Bridge appoints Peter Lebowitz to Board, joins NCG and Compensation Committees - TradingView
BridgeBio Oncology Therapeutics (NASDAQ: BBOT) appoints Peter Lebowitz to board - Stock Titan
Analysts Offer Insights on Healthcare Companies: Pyxis Oncology (PYXS), Nurix Therapeutics (NRIX) and Context Therapeutics (CNTX) - The Globe and Mail
BridgeBio started at outperform at Leerink on 'differentiated' oncology platform - MSN
BBOT Announces Multiple Presentations at the American - GlobeNewswire
This Olema Pharmaceuticals analyst begins coverage on a bullish note; here are top 4 initiations for Wednesday - MSN
Analysts Offer Insights on Healthcare Companies: Citius Oncology (CTOR) and Oruka Therapeutics (ORKA) - The Globe and Mail
Analysts Are Bullish on Top Healthcare Stocks: Elicio Therapeutics (ELTX), Silence Therapeutics (SLN) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Oric Pharmaceuticals (ORIC), MindWalk Holdings (HYFT) and Erasca (ERAS) - The Globe and Mail
CFO equity grants at BridgeBio Oncology Therapeutics (BBOT) - Stock Titan
BBOT (BBOT) Chief Scientific Officer receives new stock options and RSU grants - Stock Titan
BridgeBio Oncology (BBOT) awards stock options and RSUs to chief medical officer - Stock Titan
Analysts Are Bullish on These Healthcare Stocks: Atai Beckley N.V. (ATAI), BridgeBio Oncology Therapeutics (BBOT) - The Globe and Mail
Analysts Have Conflicting Sentiments on These Healthcare Companies: Atai Beckley N.V. (ATAI), BridgeBio Oncology Therapeutics (BBOT) and Biohaven Ltd. (BHVN) - The Globe and Mail
BBOT: Three next-gen RAS therapeutics show promising efficacy and safety, with key data due in 2026 - TradingView
BBOT: Lead G12C inhibitor and pan-KRAS assets show strong efficacy with key data expected in late 2026 - TradingView
BBOT publishes preclinical data on panKRAS inhibitor BBO-11818 By Investing.com - Investing.com Canada
Analysts Offer Insights on Healthcare Companies: BridgeBio Oncology Therapeutics (BBOT), Structure Therapeutics, Inc. Sponsored ADR (GPCR) and Ardent Health Partners, Inc. (ARDT) - The Globe and Mail
BridgeBio Oncology’s Narrow Bet on KRAS and PI3K Programs Raises Concentration Risk, Limits Strategic Flexibility - TipRanks
BBOT Announces Publication in Cancer Discovery Highlighting Preclinical Data Demonstrating BBO-11818 is a Potent and Selective panKRAS Inhibitor - Bitget
BBOT Announces Publication in Cancer Discovery Highlighting - GlobeNewswire
Bridgebio Oncology Therapeutics, Inc. Announces Publication in Cancer Discovery Highlighting Preclinical Data Demonstrating BBO-11818 is Potent and Selective panKRAS Inhibitor - marketscreener.com
Stifel reiterates Buy on BridgeBio Oncology stock, $23 target By Investing.com - Investing.com Nigeria
Stifel reiterates Buy on BridgeBio Oncology stock, $23 target - Investing.com South Africa
BBOT reports Q4 2025 results, $425M cash runway into 2028 - National Today
BridgeBio Oncology Therapeutics 10-K: Net loss $134.0M, EPS $(4.30) - TradingView
BridgeBio Oncology Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
BBOT Reports Fourth Quarter and Full Year 2025 Financial Results and Update on Corporate Progress - The Manila Times
BBOT Technical Analysis & Stock Price Forecast - Intellectia AI
HLXB Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
BridgeBio Oncology Therapeutics Inc expected to post a loss of 52 cents a shareEarnings Preview - TradingView
Analysts Offer Insights on Healthcare Companies: Tempus AI, Inc. Class A (TEM), BridgeBio Pharma (BBIO) and Establishment Labs Holdings (ESTA) - The Globe and Mail
BBOT: Novel RAS-targeted therapies show strong efficacy and safety, with major data readouts expected soon - TradingView
BBOT: Major data from three RAS-focused assets expected in H2, highlighting strong efficacy and safety - TradingView
HLXB SEC FilingsHelix Acqsn II 10-K, 10-Q, 8-K Forms - Stock Titan
BridgeBio Oncology (BBOT) Stock Analysis Report | Financials & Insights - Benzinga Japan
BBOT to Participate in Upcoming Investor Healthcare Conferences - Bitget
Stifel Initiates Coverage of BridgeBio Oncology Therapeutics (BBOT) with Buy Recommendation - Nasdaq
This Olema Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Wednesday - Benzinga
Stifel Nicolaus Initiates Coverage on BridgeBio Oncology Therapeutics With Buy Rating, $23 Price Target - marketscreener.com
Stifel initiates coverage on BridgeBio Oncology stock with Buy rating - Investing.com
Bridgebio Oncology Therapeutics Inc Stock (BBOT) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):